NEW YORK (GenomeWeb) – Roswell Park Cancer Institute subsidiary OmniSeq said today that it has received New York State Laboratory Evaluation Program approval for a 144-gene next-generation sequencing pan-cancer panel.
The OmniSeq Comprehensive Panel is designed to molecularly profile tumors in order to guide treatment decisions. It provides information on genes linked to more than 650 therapies and 850 clinical trials and can identify drugs that would not be appropriate for certain patients due to their genomic profile, according to the company.
The panel uses Thermo Fisher Scientific's Oncomine reagents and runs on its Ion Torrent sequencing system.
OmniSeq also said it will partner with Cure Forward to help match patients who have been molecularly profiled to appropriate clinical trials. Under the collaboration, patients can access their OmniSeq Comprehensive Panel test results online and use Cure Forward's Clinical Trial Exchange Platform to understand their treatment options. Trial sponsors can also identify patients who match their selection criteria and invite them to apply to their studies.
"Patients and their families are becoming increasingly active participants in devising strategies for their care," Martin Naley, founder and chief strategy officer of Cure Forward, said in a statement.
"Cure Forward offers a unique platform that proactively connects patients to clinical trials, which fits perfectly into our mission as we offer patients more than just therapeutically actionable molecular diagnostic testing, but a complete service experience," Mark Gardner, CEO of OmniSeq, said in a statement.